B-hCD19 MC38_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

Common name	B-hCD19 MC38	Catalog number	310706
Aliases	CD19, CD19 molecule, B4, CVID3	Disease	Colon carcinoma
Organism	Mouse	Strain	C57BL/6
Tissue types	Colon	Tissue	Colon

Description

The mouse Cd19 gene was replaced by human CD19 coding sequence in B-hCD19 MC38 cells. Human CD19 is highly expressed on the surface of B-hCD19 MC38 cells.

Application

B-hCD19 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Targeting strategy

Gene targeting strategy for B-hCD19 MC38 cells. The exogenous promoter and human CD19 coding sequence was inserted to replace part of murine exon 2 and all of exons 3~12. The insertion disrupts the endogenous murine Cd19 gene, resulting in a non-functional transcript.

Protein expression analysis

CD19 expression analysis in B-hCD19 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD19 MC38 cultures were stained with species-specific anti-CD19 antibody. Human CD19 was detected on the surface of B-hCD19 MC38 cells but not wild-type MC38 cells. The 2-G1 clone of B-hCD19 MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hCD19 MC38 cells. B-hCD19 MC38 cells (5x10⁵⁾ and wild-type MC38 cells (5x10⁵) were subcutaneously implanted into C57BL/6 mice (female, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hCD19 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.